These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7683344)

  • 1. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells.
    Fong CJ; Sutkowski DM; Braun EJ; Bauer KD; Sherwood ER; Lee C; Kozlowski JM
    J Urol; 1993 May; 149(5):1190-4. PubMed ID: 7683344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triiodothyronine modulates growth, secretory function and androgen receptor concentration in the prostatic carcinoma cell line LNCaP.
    Esquenet M; Swinnen JV; Heyns W; Verhoeven G
    Mol Cell Endocrinol; 1995 Mar; 109(1):105-11. PubMed ID: 7540569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone.
    Lee C; Sutkowski DM; Sensibar JA; Zelner D; Kim I; Amsel I; Shaw N; Prins GS; Kozlowski JM
    Endocrinology; 1995 Feb; 136(2):796-803. PubMed ID: 7530653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY; Ly LH; Peehl DM; Feldman D
    Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate.
    Esquenet M; Swinnen JV; Heyns W; Verhoeven G
    Prostate; 1996 Mar; 28(3):182-94. PubMed ID: 8628721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of androgenic regulation by brefeldin A in androgen-responsive prostate cancer cells.
    Alexander B; Fishman AI; Green D; Choudhury MS; Konno S
    Urol Oncol; 2013 Jan; 31(1):104-9. PubMed ID: 21795077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
    Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP.
    Berns EM; de Boer W; Mulder E
    Prostate; 1986; 9(3):247-59. PubMed ID: 2946029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LNCaP prostatic adenocarcinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids.
    Esquenet M; Swinnen JV; Heyns W; Verhoeven G
    J Steroid Biochem Mol Biol; 1997 Aug; 62(5-6):391-9. PubMed ID: 9449242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen and retinoic acid interaction in LNCaP cells, effects on cell proliferation and expression of retinoic acid receptors and epidermal growth factor receptor.
    Li MT; Richter F; Chang C; Irwin RJ; Huang H
    BMC Cancer; 2002 Jun; 2():16. PubMed ID: 12069693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactive effects of 9-cis-retinoic acid and androgen on proliferation, differentiation, and apoptosis of LNCaP prostate cancer cells.
    Eskra JN; Kuiper JW; Walden PD; Bosland MC; Özten N
    Eur J Cancer Prev; 2017 Jan; 26(1):71-77. PubMed ID: 26886237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
    Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of prostatic carcinoma cell proliferation and secretory activity by extracellular matrix and stromal secretions.
    Fong CJ; Sherwood ER; Braun EJ; Berg LA; Lee C; Kozlowski JM
    Prostate; 1992; 21(2):121-31. PubMed ID: 1384014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP.
    Joly-Pharaboz MO; Soave MC; Nicolas B; Mebarki F; Renaud M; Foury O; Morel Y; Andre JG
    J Steroid Biochem Mol Biol; 1995 Oct; 55(1):67-76. PubMed ID: 7577722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP.
    Langeler EG; van Uffelen CJ; Blankenstein MA; van Steenbrugge GJ; Mulder E
    Prostate; 1993; 23(3):213-23. PubMed ID: 7694266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells.
    Ripple MO; Henry WF; Rago RP; Wilding G
    J Natl Cancer Inst; 1997 Jan; 89(1):40-8. PubMed ID: 8978405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
    Zhao XY; Peehl DM; Navone NM; Feldman D
    Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells.
    Sherwood ER; Van Dongen JL; Wood CG; Liao S; Kozlowski JM; Lee C
    Br J Cancer; 1998 Mar; 77(6):855-61. PubMed ID: 9528825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP.
    Kim IY; Kim JH; Zelner DJ; Ahn HJ; Sensibar JA; Lee C
    Endocrinology; 1996 Mar; 137(3):991-9. PubMed ID: 8603613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.